PROJECT SUIVIMARY (See instructions): Core C (Biostatistics &Data Management) provides expert guidance and collaboration in the biostatistical aCore C (Biostatistics &Data Management) provides expert guidance and collaboration in the biostatistical and data management aspects of the design, conduct and analysis of translational research projects generated by the POI. Prior to the initiation of studies. Core staff members consult with POI investigators to help select designs that are efficient and adequately powered. As studies proceed, staff members review data periodically to evaluate adherence to study procedures, data quality, and adequacy of underlying statistical assumptions. When studies are finished, staff members review the data again, produce informative summary tables and graphical displays, conduct correct and efficient statistical analyses, and consult on the design of subsequent studies. Core C data management staff assist Project 1 investigators with the implementation of clinical trials by designing data collection forms, establishing data management systems, managing data, executing data quality control activities, preparing analysis files, producing interim data completeness reports, and archiving data from completed studies. The work of Core C involves close integration with the efforts of all the research projects. Core C staff members have extensive experience supporting cancer research, with strong backgrounds in basic science, translational research, clinical trials, research computing, and data management. With their many years of experience in biomedical research, they stand ready to identify and apply ideal methods for the statistical design and analysis and data management of POI research studies. Core C offers its sen/ices to all P01 projects and cores.
Malignant mesothelioma is currently considered incurable. New approaches are needed. This Core provides the statistical and data management sen/ices to support the clinical and preclinical studies of the Program Project..
|Maus, Marcela V; Fraietta, Joseph A; Levine, Bruce L et al. (2014) Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 32:189-225|
|Singh, Nathan; Liu, Xiaojun; Hulitt, Jessica et al. (2014) Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol Res 2:1059-70|
|Wang, Liang-Chuan S; Lo, Albert; Scholler, John et al. (2014) Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2:154-66|
|Barrett, David M; Singh, Nathan; Liu, Xiaojun et al. (2014) Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 16:619-30|
|Moon, Edmund K; Wang, Liang-Chuan; Dolfi, Douglas V et al. (2014) Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 20:4262-73|
|Beatty, Gregory L; Haas, Andrew R; Maus, Marcela V et al. (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2:112-20|
|Vonderheide, Robert H; June, Carl H (2014) Engineering T cells for cancer: our synthetic future. Immunol Rev 257:7-13|
|Fridlender, Z G; Jassar, A; Mishalian, I et al. (2013) Using macrophage activation to augment immunotherapy of established tumours. Br J Cancer 108:1288-97|
|Baek, Kwan-Hyuck; Bhang, Dongha; Zaslavsky, Alexander et al. (2013) Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. J Clin Invest 123:4375-89|
|Quatromoni, Jon G; Suzuki, Eiji; Okusanya, Olugbenga et al. (2013) The timing of TGF-* inhibition affects the generation of antigen-specific CD8+ T cells. BMC Immunol 14:30|
Showing the most recent 10 out of 66 publications